***Where can I find information on the ongoing MARINE patent ANDA litigation appeal and what is Amarin's policy regarding updates as the litigation and related events progress?***

As announced on March 30, 2020, the United States District Court for the District of Nevada ruled in favor of the generic companies in Amarin's patent litigation against two filers of abbreviated new drug applications, or ANDAs, for Amarin's VASCEPA® (icosapent ethyl) capsule franchise.

For a generic product to be launched in the United State the generic company's ANDA must be approved by the U.S. Food and Drug Administration, or FDA. For the latest updates on this matter, investors are encouraged to monitor the FDA website and public statements from the generic companies in the litigation. While Amarin plans to update investors as appropriate, it does not undertake to provide the most current information available.

Once a generic company's ANDA is approved at FDA, and if the generic company has sufficient commercial supply available, that generic company may choose to launch its generic product in the United States. If a generic product is launched and the district court judgment is later overruled by a judgment in Amarin's favor, the generic company would then be subject to liability to Amarin for patent infringement. Damages in such cases are typically equal to at least the brand's lost profits caused by the generic sales. Because a branded company's lost profit is typically higher than a generic company's profit, such a launch is considered risky for the generic company. Due to such risk, more often than not, generic companies choose to not undertake such a launch at risk. There can be no guarantee against a generic launch.

If a generic launch occurs, Amarin does not believe generic companies have made the investment of resources, know-how and time to develop sufficient quantities of quality supply to meet current and growing demand at or near the level supplied by Amarin. Amarin's belief is based on its understanding of the investment, know-how and time required to manufacture large quantities of such supply, the complex nature of manufacturing VASCEPA to the required standards and our assessment of currently available information (as informed by our knowledge of market dynamics) regarding the general lack of large quantities of such supply available on short notice. It has required many years and significant investment and commitments by Amarin to develop high capacity, consistent, cost effective, high-quality, stable supply of VASCEPA. The active ingredient in VASCEPA is a fragile molecule. VASCEPA clinical results were achieved through use of product manufactured to the high-quality standards developed by Amarin over years, which include high purity levels, protection against oxidation and product stability through active ingredient manufacturing, encapsulation and distribution. Starting with raw material, the various steps taken to produce VASCEPA to high standards at commercial capacity typically takes several months including international shipping.

Amarin strongly disagrees with the district court ruling and will vigorously pursue its appeal of the lower court's decision. Amarin believes it has a strong balance sheet with capacity and flexibility and plans to fight to protect the VASCEPA franchise for the benefit of our patients, physicians, the broader healthcare community and our investors. Based on current market dynamics, as Amarin works to take appropriate legal actions to defend and protect its intellectual property, it plans to continue to press forward with educational and promotional efforts for VASCEPA in treating indicated patients at high risk of cardiovascular events, such as heart attack and stroke.

Accordingly, on April 2, 2020, Amarin filed an appeal of the district court ruling. Amarin has no immediate plan to file a preliminary injunction against launch, due to a variety of factors, including that Amarin's

request for an expedited appeal was approved and therefore Amarin anticipates the appeal will be able to move expeditiously to a Federal Circuit ruling. Amarin believes it is favorably situated to prevail on appeal and restore its exclusivity position in the United States. The timing of such appeal proceedings and an outcome on the merits is difficult to predict. It is not uncommon for such an appeal to take from several months to approximately one year until judgment. It can sometimes be longer.

If a generic company with ANDA approval is able to supply the product in significant commercial quantities, and the status quo in the market for VASCEPA is not maintained, the introduction of generic versions of VASCEPA could significantly affect the market for Amarin's VASCEPA, subject to patent infringement liability such as lost profit damages in favor of Amarin should Amarin prevail on appeal. At this time, Amarin is giving legal priority to the current appeal process.

Updates on litigation proceedings are available through legal systems such as PACER. Amarin plans to update stakeholders with the results of the litigation once they are published by the Court. For more information on the ANDA litigation process please see Amarin's latest 10-K/10-Q on file with the U.S. Securities and Exchange Commission, as updated by subsequent reports such as form 8-Ks.

Dated May 27, 2020